I Peace Selected as a TOP 10 Awardee for the "Top 10 Longevity Breakthrough Awards 2026"
PALO ALTO, Calif., Oct. 1, 2026 /PRNewswire/ -- I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPS cell) technologies for regenerative medicine and longevity, today announced that it was selected as one of the awardees for the Top 10 Longevity Breakthrough Awards at the 2026 Asia-Pacific Healthy Longevity International Summit. The award was presented for I Peace's research and development of iPSF, a cell-free product derived from culture supernatant of iPS cells.
"We are honored to be recognized as one of this year's Top 10 Longevity Breakthrough award recipients," said Dr. Koji Tanabe, Founder and CEO of I Peace, Inc. "This recognition reflects our team's commitment to advancing the possibilities of iPS cell technology and exploring new approaches in the longevity field. We are proud to be included among such respected innovators and look forward to continuing our efforts to progress iPSC science."
The Longevity Breakthrough Awards recognizes innovative technologies and research with the potential to contribute to healthy longevity, based on scientific and medical evidence.
A Cell-Free Technology Focused on Components Derived from iPS Cells
Research and development in regenerative medicine using iPS cells is advancing worldwide, with clinical trials currently underway across multiple disease areas. Findings from these studies suggest that the therapeutic effects of iPSC-derived cells may arise not only from the engraftment and replacement of damaged tissues, but also from various bioactive factors released by these cells that influence surrounding cells and tissues.
Focusing on these intercellular signaling mechanisms, I Peace has been developing iPSF as a cell-free technology that utilizes components derived from iPSC-derived cells, rather than administering the cells themselves.
Researching Potential Applications for Age-Related Cellular and Tissue Changes
iPSF is obtained by isolating and purifying factors produced during the culture supernatant of iPSC-derived cells. Research conducted to date has observed changes related to extracellular matrix production and aging-associated biomarkers. I Peace is currently investigating the underlying mechanisms of action, as well as the safety and potential utility of iPSF.
In addition, the company is conducting foundational research and exploratory evaluations into potential applications for various tissues whose function may decline with age, including skin and hair. Going forward, I Peace plans to carefully assess reproducibility, safety, and clinical relevance through appropriately designed studies.
Bringing iPS Cell Technology to the Longevity Field
In recent years, research and development in longevity medicine has expanded rapidly worldwide, with scientists seeking to understand the biological mechanisms of aging and develop interventions for age-related diseases and functional decline. Within the field of iPS cell research, interest has also grown beyond tissue regeneration through cell transplantation to include areas such as cellular rejuvenation, intercellular signaling, and improvement of the tissue environment, all of which may contribute to extending healthy lifespan.
I Peace's business and research activities are centered around three key pillars:
- Manufacturing clinical-grade and research-grade iPS cells for pharmaceutical companies and research institutions through the GMPeace service.
- Providing personal iPS cell banking services to help individuals prepare for future medical advances through the My Peace service.
- Conducting longevity-focused research and development based on iPS cell technologies.
Through this award, I Peace will continue to explore new possibilities for iPS cell technology while contributing to the extension of healthy lifespan worldwide and the advancement of the iPS cell manufacturing industry.
Note: iPSF is currently in the research and development stage and is not an approved pharmaceutical product intended to treat, prevent, or mitigate any specific disease.
About I Peace, Inc.
I Peace, Inc. is a biotechnology company pioneering the clinical and commercial application of induced pluripotent stem cell (iPSC) technologies for regenerative medicine and longevity. The company was founded in 2015 by Dr. Koji Tanabe, PhD, a leading expert in iPSC technology and an early pioneer of the field. Dr. Tanabe trained in Professor Shinya Yamanaka's laboratory at Kyoto University and was the second author of the landmark research reporting the world's first successful establishment of human iPS cells. This scientific heritage emphasizes I Peace's commitment to advancing rigorous, high-quality iPSC science.
I Peace offers global services for individuals and enterprise partners, including personal iPSC banking from My Peace, as well as GMP‑compliant manufacturing, drug development, and global supply of clinical‑grade iPSCs from GMPeace. In parallel, the company is advancing the role of iPSC technology in the longevity and rejuvenation space through a strategic collaboration with Reju, Inc., highlighting the broad and transformative potential of iPSCs for improving human health. I Peace envisions a future where iPSC-derived therapies are readily available to everyone and where the use of iPSCs becomes a routine part of everyday healthcare. For more information, please visit https://ipeace.com/en/.
About My Peace
My Peace is a personal iPS cell banking service provided by I Peace, Inc. that helps individuals prepare for potential future regenerative medicines by developing and storing their own iPS cells. The process starts with a scheduled blood draw, followed by the clinical-grade manufacturing of the customer's iPS cells. My Peace is supported by I Peace's iPSC manufacturing expertise, offering customers their own personalized cell resource that can be used for future potential autologous therapeutics. For more information, visit https://mypeace-personal-ipscbanking.com/en/.
I Peace Media Contact
[email protected]
SOURCE I Peace, Inc.
Share this article